Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
Read Original Article: Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard »
